361 related articles for article (PubMed ID: 32418917)
1. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
[TBL] [Abstract][Full Text] [Related]
2. Targeting T-cell senescence and cytokine storm with rapamycin to prevent severe progression in COVID-19.
Omarjee L; Janin A; Perrot F; Laviolle B; Meilhac O; Mahe G
Clin Immunol; 2020 Jul; 216():108464. PubMed ID: 32405269
[No Abstract] [Full Text] [Related]
3. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
Ratajczak MZ; Kucia M
Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
[TBL] [Abstract][Full Text] [Related]
5. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
Theoharides TC
Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
[No Abstract] [Full Text] [Related]
6. Active Therapy with Passive Immunotherapy May Be Effective in the Fight against COVID-19.
Morabito CJ; Gangadharan B
Clin Transl Sci; 2020 Sep; 13(5):835-837. PubMed ID: 32420691
[No Abstract] [Full Text] [Related]
7. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
Li H; Liu Z; Ge J
J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
[TBL] [Abstract][Full Text] [Related]
8. Overview of lethal human coronaviruses.
Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Vaccine: A comprehensive status report.
Kaur SP; Gupta V
Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
[TBL] [Abstract][Full Text] [Related]
10. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2.
Gupta SP
Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613
[TBL] [Abstract][Full Text] [Related]
11. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
12. COVID-19: Immunology and treatment options.
Felsenstein S; Herbert JA; McNamara PS; Hedrich CM
Clin Immunol; 2020 Jun; 215():108448. PubMed ID: 32353634
[TBL] [Abstract][Full Text] [Related]
13. CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement.
Ulrich H; Pillat MM
Stem Cell Rev Rep; 2020 Jun; 16(3):434-440. PubMed ID: 32307653
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Giovane RA; Rezai S; Cleland E; Henderson CE
Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
[TBL] [Abstract][Full Text] [Related]
15. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development.
Samrat SK; Tharappel AM; Li Z; Li H
Virus Res; 2020 Oct; 288():198141. PubMed ID: 32846196
[TBL] [Abstract][Full Text] [Related]
16. Lessons from dermatology about inflammatory responses in Covid-19.
Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
[TBL] [Abstract][Full Text] [Related]
17. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
Saxena A
J Biosci; 2020; 45(1):. PubMed ID: 32661214
[TBL] [Abstract][Full Text] [Related]
18. Potential strategies for combating COVID-19.
Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
[TBL] [Abstract][Full Text] [Related]
19. Targeting innate immunity by blocking CD14: Novel approach to control inflammation and organ dysfunction in COVID-19 illness.
Martin TR; Wurfel MM; Zanoni I; Ulevitch R
EBioMedicine; 2020 Jul; 57():102836. PubMed ID: 32574958
[TBL] [Abstract][Full Text] [Related]
20. Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Manjaly Thomas ZR; Leuppi-Taegtmeyer A; Jamiolkowski D; Steveling-Klein E; Bellutti-Enders F; Scherer Hofmeier K; Hartmann K
J Allergy Clin Immunol; 2020 Oct; 146(4):786-789. PubMed ID: 32710973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
